RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data

AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation dat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kafatos, George, Niepel, Daniela, Lowe, Kimberley, Jenkins-Anderson, Sophie, Westhead, Hal, Garawin, Tamer, Traugottová, Zuzana, Bilalis, Antonios, Molnar, Edit, Timar, Jozsef, Toth, Erika, Gouvas, Nikolaos, Papaxoinis, George, Murray, Samuel, Mokhtar, Nadia, Vosmikova, Hana, Fabian, Pavel, Skalova, Alena, Wójcik, Piotr, Tysarowski, Andrzej, Barugel, Mario, van Krieken, J Han, Trojan, Jörg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6367778/
https://www.ncbi.nlm.nih.gov/pubmed/28747067
http://dx.doi.org/10.2217/bmm-2016-0358
Descripción
Sumario:AIM: A confirmed wild-type RAS tumor status is commonly required for prescribing anti-EGFR treatment for metastatic colorectal cancer. This noninterventional, observational research project estimated RAS mutation prevalence from real-world sources. MATERIALS & METHODS: Aggregate RAS mutation data were collected from 12 sources in three regions. Each source was analyzed separately; pooled prevalence estimates were then derived from meta-analyses. RESULTS: The pooled RAS mutation prevalence from 4431 tumor samples tested for RAS mutation status was estimated to be 43.6% (95% CI: 38.8–48.5%); ranging from 33.7% (95% CI: 28.4–39.3%) to 54.1% (95% CI: 51.7–56.5%) between sources. CONCLUSION: The RAS mutation prevalence estimates varied among sources. The reasons for this are not clear and highlight the need for further research.

Ejemplares similares